Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma

Chinese Journal of Cancer

Volumn 31, Issue 10, 2012, Pages 476-483

  Zhao, Li Ping ^a   Xue, Cong ^a   Zhang, Jian Wei ^a   Hu, Zhi Huang ^a   Zhao, Yuan Yuan ^a   Zhang, Jing ^a   Huang, Yan ^a   Zhao, Hong Yun ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Gemcitabine; Immunohistochemistry; Nasopharyngeal carcinoma; RRM1

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NASOPHARYNX CARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84867509337     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10029     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005,55:74-108.
2. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol, 2002,13:1007-1015.
3. O'Sullivan B. Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2007,69: S118-S221.
4. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-an alysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys, 2006,64:47-56.
5. Al-Sa rraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol, 1998,16:1310-1317.
6. Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2009,20:123-125.
7. Fandi A, Bachouchi M, Azli N, et al. Long-te rm disease-fre e survivors in metastatic undifferentiated carcinoma of naso-pharyngeal type. J Clin Oncol, 2000,18:1324-1330.
8. Rosell R, Cecere F, Santarpia M, et al. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharm, 2006,6: 323-331.
9. Crinò L, Foglietta J, Hamzaj A. Lung cancer. J Thorac Oncol, 2007,2:24-26.
10. Shi X, Yuan X, Tao D, et al. Analysis of DNA ploidy, cell cycle and Ki67 antigen in nasopharyngeal carcinoma by flow cytometry. J Huazhong Univ Sci Technolog Med Sci, 2005,25: 198-201.
11. Zhao GQ, Xu Y, Wang Q. Significance of serum vascular endothelial growth factor test before radiotherapy in patients with nasopharyngeal carcinoma. Zhong Xi Yi Jie He Xue Bao, 2005,3:274-277. [in Chinese]
12. Mai HQ, Zeng ZY, Zhang CQ, et al. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer, 2006,106:1548-1553.
13. Doustjalali SR, Yusof R, Govindasamy GK, et al. Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression. J Med Invest, 2006,53:20-28.
14. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res, 2004,10:43-52.
15. Fan H, Huang A, Villegas C, et al. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA, 1997,94:13181-13186.
16. Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-ba sed chemotherapy. Cancer Chemother Pharmacol, 2008,61:33-38.
17. Ma BB, Tannock IF, Pond GR, et al. Chemotherapy with gemcitabine-co ntaining regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer, 2002,95:2516-2523.
18. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol, 2002,13:1252-1258.
19. FooKF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol, 2002,13:150-156.
20. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004,64:3761-3766.
21. Bergman AM, Eijk PP, Ruiz VHV, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res, 2005,65:9510-9516.
22. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol, 2006,24:4731-4737.
23. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer, 2007,120:1355-1363.
24. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs, 1992,10:239-253.
25. Wang X, Zhao J, Yang L, et al. Positive expression of ERCC1 predicts a poorer platinum-ba sed treatment outcome in Chinese patients with advanced non-sm all-cell lung cancer. Med Oncol, 2010,27:484-490.
26. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999,286:487-491.
27. Evans WE, McLeod HL. Pharmacogenomics drug disposition, drug targets, and side effects. N Engl J Med, 2003,348:538-549.
28. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer, 2007,120:1355-1363.
29. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-tre ated advanced non-small cell lung cancer patients. Clin Cancer Res, 2004,10:1318-1325
30. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-di rected individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol, 2007,25:2741-2746.
31. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol, 2006,17:1818-1825.
32. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-fre e survival in patients with non-small-cell lung cancer. J Clin Oncol, 2004, 22:1878-1885.